1. Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection 
J. Stuart Elborn, Patrick A. Flume, Fredric Cohen, Jeffery Loutit, Donald R. VanDevanter 
Journal of Cystic Fibrosis 
Volume 15, Issue 5, Pages (September 2016)
DOI: /j.jcf
Copyright © Terms and Conditions

2. Fig. 1
Study design.
Abbreviations: BID, twice daily; LIS, levofloxacin inhaled solution; RCT, randomized control trial [10]; TIS, tobramycin inhalation solution.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © Terms and Conditions

3. Fig. 2 Patient disposition.
Abbreviations: AE, adverse event; LIS, levofloxacin inhaled solution 240mg twice daily; TIS, tobramycin inhalation solution 300mg twice daily.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © Terms and Conditions

4. Fig. 3
Relative changes in FEV1% predicted from RCT baseline to day 336. On the left are data from the intent-to-treat population of the RCT [10]; on the right are those subjects who received ≥1 dose of LIS in the extension. Complete data from only those patients who participated in the extension study may be seen in Fig. S2. Error bars indicate standard error. Abbreviations: LIS, levofloxacin inhaled solution 240mg twice daily; TIS, tobramycin inhalation solution 300mg twice daily.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © Terms and Conditions